Resverlogix Highlights Potential to Develop Apabetalone as a Therapeutic for HIV-1 Eradication Utilizing the "Shock and Kill" Approach
Based on a growing body of data demonstrating apabetalone's beneficial attributes as a latency-reversing agent for advancing HIV-1 eradication, Resverlogix is seeking a partner for future development
CALGARY, Alberta and BOSTON, June 07, 2018 (GLOBE NEWSWIRE) -- Based on recent findings on apabetalone's potential role in human immunodeficiency virus ("HIV-1") eradication, Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is seeking a partnership with an existing stakeholder in the ongoing fight against HIV-1. The most recent publication titled: "The BET bromodomain inhibitor apabetalone induces apoptosis of latent HIV-1 reservoir cells following viral reactivation," in Nature's Acta Pharmacologica Sinica (2018) 0:1-13; demonstrated apabetalone's abilities to expose and reactivate latent HIV-1 reservoirs, induce HIV-1 latent cell death, and reduce the side effects of standard of care (cART combination antiretroviral therapy).
"Bromodomain and extra-terminal (BET) proteins play a role in maintaining HIV-1 in latent cell reservoirs inaccessible to anti-viral agents. The virus hiding within the cells is the primary reason for treatment failure and the inability to fully eliminate the virus from a patient. Treatment with the BD2 selective BET inhibitor apabetalone results in the activation and release of the virus from the cells, allowing it to be targeted for eradication by concurrent anti-viral therapy," stated Ewelina Kulikowski, Senior Vice President of Research and Development.
"Apabetalone's unique epigenetic mechanism of action has once again been tied to another important grievous disease for which there is no cure. In order to help expedite development in this space, interested HIV/AIDS stakeholders such as patient advocacy groups, government health bodies, major phamaceutical companies, and/or non-government research organization (NRO's) are encouraged to contact Resverlogix to further the research and development of apabetalone as a therapeutic for HIV-1 eradication," stated Donald McCaffrey, President & CEO of Resverlogix.
Resverlogix continues the development of apabetalone in high-risk CVD patients with type 2 diabetes mellitus and low levels of high-density lipoprotein (HDL), as well as in chronic kidney disease and Fabry disease.
About HIV & HIV Latency
According to the UNAIDS foundation there was an estimated 36.7 million people living with HIV globally in 2016, of which 20.9 million people were estimated to be accessing HIV antiretroviral therapy by June 2017. The treatment for HIV is a lifelong process requiring continuous medication. Reducing the frequency with which medication needs to be taken would not only improve quality of life and adherence to therapies, but also decrease the economic burden associated with HIV treatment. Latent HIV-1 reservoirs are the main cause of treatment failure. Latency reversal agents (LRAs) which would deplete latent HIV reservoirs, in conjunction with combination anti-retroviral agents, would allow for effective killing and eradication of HIV.
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease (CVD), diabetes mellitus (DM), chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile. Apabetalone is currently being studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM and low high-density lipoprotein (HDL). In BETonMACE approximately 11% of the participants have chronic kidney disease.
The Company's kidney program is assessing apabetalone's effect in non-dialysis patients as well as in patients on dialysis with the eventual objective of addressing the huge medical need and demonstrate improved health outcomes.
Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).
Follow us on Twitter: @Resverlogix_RVX
For further information please contact:
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to, and the potential role of apabetalone in the treatment of HIV-1, AIDS, CVD, DM, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Resverlogix Corp via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Elemica Wins Three Prestigious Supply Chain Awards This Month25.6.2019 17:03:00 CEST | Pressemelding
Elemica Awarded for Creating Supply Chain Excellence With Next-Gen Technologies ATLANTA, June 25, 2019 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturing industries, announces that the company has been honored with two top supply chain awards, and Gary Neights, Senior Director of Product Management at Elemica, was named a Top 50 Tech Visionary. “The industry is recognizing Elemica and its people for their innovative solutions and robust platform that produces exceptional business results for clients,” said David Cahn, Director of Global Marketing at Elemica. “Elemica has been instrumental this year in helping numerous global businesses move forward on their digital transformations, resulting in improved visibility, greater efficiencies, and better bottom line results.” Supply & Demand Chain Executive has selected Elemica as a recipient of the SDCE 100 Award for the 7th consecutive year. Food Logistics magazine has bestowed Elemica with a Top Green
cPacket Networks to Offer Cloud Visibility Service with Amazon Virtual Private Cloud Traffic Mirroring25.6.2019 17:00:00 CEST | Pressemelding
New cCloud Solution Provides Customers Access to Network-Level Packet Data for Performance and Security Monitoring SAN JOSE, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- cPacket Networks, a leading provider of next-generation network performance/security monitoring and packet brokering solutions, has launched the cCloud cloud-based network visibility-as-a-service (VaaS) offering by working with Amazon Web Services (AWS) and leveraging the traffic mirroring feature offered by Amazon Virtual Private Cloud (Amazon VPC). “While many of our customers are migrating workloads to the cloud, until now it happened to be a black-box for them, from a performance and security perspective. The cPacket solution builds on Amazon Virtual Private Cloud (Amazon VPC) traffic mirroring to remove blind spots, provide complete visibility, and make the cloud transition smooth for our customers,” said Brendan O’Flaherty, CEO of cPacket Networks. Without the rich insights of packet data, full visibility is comprom
PowerPlan Expands Leadership Team To Support Continued Company Growth25.6.2019 16:42:00 CEST | Pressemelding
ATLANTA, June 25, 2019 (GLOBE NEWSWIRE) -- PowerPlan, Inc., a leading provider of strategic corporate performance management for asset-intensive companies, announced today the appointment of Brett Bertz as its Chief Customer Officer and John Budala as its Chief Information Officer. These two positions, new to PowerPlan, will help the company sustain growth in the areas of customer success and technological infrastructure. Bertz and Budala report directly to the company’s CEO, Joe Gomes. “As PowerPlan continues to evolve to meet the needs of our customers, we are thrilled to have Brett and John join our leadership team,” said Gomes. “Brett and John have invaluable experience and have proven to lead through innovation.” Both Bertz and Budala join PowerPlan with extensive experience meeting and exceeding the needs of their customers, and building strong, progressive relationships with industry partners and their internal teams. Bertz has a history of building customer-centric cultures. He
NEP Group Acquires HDR, Expanding Its Broadcast and Media Solutions Capabilities in Europe and Worldwide25.6.2019 16:22:00 CEST | Pressemelding
PITTSBURGH, Pa. USA, June 25, 2019 (GLOBE NEWSWIRE) -- NEP Group, the leading worldwide outsourced technical production partner supporting premier content producers of live sports and entertainment, announced that it has signed a definitive agreement to purchase HDR Group, a full-service production partner headquartered in Stockholm, Sweden. The agreement became effective on June 17, 2019, and the deal is expected to close in early Q3 or Q4 of this year, conditional upon the approval of the Swedish Competition Authority. Prior to closing, NEP and HDR will continue to operate as separate and independent companies. HDR was founded in 2007 and today employs more than 100 employees who support clients in the live sports, entertainment and broadcast markets in Sweden, Norway, Denmark and Finland. The addition of HDR is consistent with NEP’s stated strategy to become the world leader in Broadcast Services and Media Solutions and increases NEP’s ability to serve its clients in the Nordic regi
Kim Crawford Wines Partners With US Open Tennis Championships25.6.2019 16:00:00 CEST | Pressemelding
No. 1-Selling Sauvignon Blanc in U.S. Becomes the Official Wine of the US Open Tennis Championships in New, Multi-Year Agreement WHITE PLAINS, N.Y. and MARLBOROUGH, New Zealand, June 25, 2019 (GLOBE NEWSWIRE) -- The United States Tennis Association (USTA) and Kim Crawford Wines today announced a new partnership that names Kim Crawford Wines as the official wine of the US Open Tennis Championships. The new, multi-year agreement commences with the 2019 Open. The No. 1-selling Sauvignon Blanci and leading New Zealand wine brandii in the U.S., Kim Crawford Wines will #ServeUpKim to US Open fans with a permanent brand presence on the grounds of the USTA Billie Jean King National Tennis Center. Kim Crawford will further support the partnership at retail locations across the country with impactful displays and an exciting sweepstakes, in which the winner will receive an all-expenses paid VIP experience at the 2020 US Open. The sweepstakes begins July 1 and ends August 31, during which consume
Appian Announces Winners of its Annual Hackathon at Appian World25.6.2019 15:00:00 CEST | Pressemelding
RESTON, Va., June 25, 2019 (GLOBE NEWSWIRE) -- Appian (NASDAQ: APPN) congratulates the winners of the Appian World 2019 Hackathon. Participants were tasked with leveraging the Appian platform to showcase the effectiveness and speed of low-code development. Hundreds of registrations were narrowed down to three winners by a seasoned panel of judges including Black Girls Code Founder and CEO, Kimberly Bryant and Neil Ward-Dutton, IDC’s VP of AI and DX European Research Practices and Appian executives. Finalists attended Appian World 2019 in San Diego, CA where they showcased their solutions to the all-star panel of judges. The judges based their decisions on the originality of the idea underlying the application, how well that idea was executed by the developer, and the beneficial impact of the solution. The submissions, covering a variety of industries and use cases, all exemplified the power and simplicity of building enterprise applications on the Appian platform. The 2019 winners are: